Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's ...

Medicare covers weight loss drugs including Ozempic under specific conditions when the drug also has potential use cases beyond weight loss.

In this week’s InnovationRx newsletter, we look at longevity drugs for dogs, programmable mRNA for fighting cancer, AI models ...

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as ...

Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to ...

A wide variety of unapproved FDA drugs were discovered during inspections, including nearly 55,000 fake injectables and pills ...